Skip to main content
HCP check
HCP check

Welcome to SHPT Challenges

This website contains information about secondary hyperparathyroidism (SHPT). It is intended to provide information to an international audience outside of the USA.

You are now leaving our website and heading to a third-party website that we do not operate. We are not responsible for the content of the third-party website. You are advised to review its privacy policy as it may differ from ours.

Are you sure you want to leave?

Confirm

Cancel

Watch our symposium about expert approaches to managing CKD–MBD

12 June 2020

Vifor Pharma made a virtual splash at the 2020 ERA–EDTA Congress

Adapting to the state of lockdown imposed by COVID-19, the 2020 European Renal Association–European Dialysis and Transplant Association (ERA–EDTA) Congress went online. We were there to raise awareness about secondary hyperparathyroidism (SHPT) and chronic kidney disease–mineral and bone disorder (CKD–MBD) by running a virtual symposium and hosting a virtual booth. Access to online videos of the symposium and highlights about the booth are provided below.

The virtual symposium featured expert opinions on CKD–MBD management

Watch the teaser video now. For the full-length presentations, please see the link below.

 

 

Our symposium, which was entitled ‘Expert approaches to management across the CKD–MBD continuum’, gave attendees the opportunity to explore the latest expert opinions on managing SHPT in non-dialysis patients and controlling hyperphosphataemia in dialysis patients.

The symposium was chaired by Dr Smeeta Sinha* and included two presentations:

  1. Evolving opportunities to optimise SHPT management, by Professor Mario Cozzolino
  2. Effective control of hyperphosphataemia: the phosphate–protein dilemma, by Professor Kamyar Kalantar-Zadeh

If you missed the symposium, you can watch it online right now.

The virtual booth raised awareness about SHPT and other CKD-related disorders

Our virtual booth was divided into three sections, raising awareness about:

  1. SHPT
  2. Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV)
  3. CKD-associated pruritis

Addressing the unmet needs in CKD patients

The SHPT section of the booth provided access to many of the features available on this website, allowing attendees to:

  • Explore the pathogenesis of SHPT, along with new data on the relationships between parathyroid hormone (PTH) levels, fractures, vascular events and death, through the interactive disease awareness aid available in the Learn section of this website
  • Download our booklets about the challenges of treating SHPT and KDIGO’s guidelines on the management of CKD–MBD, accessible on our Download page
  • Watch our creative animation about the unmet needs of SHPT treatment, available via our Watch page
  • Test their SHPT knowledge by taking our online SHPT Challenge, now available at SHPTchallenge.com

We’d like to extend our gratitude to all involved in delivering our booth and symposium, especially the Chair, Dr Sinha, and our distinguished speakers, professors Cozzolino and Kalantar-Zadeh.

 

Footnote

*North West England Renal Network Chair; National Health Service; Manchester, United Kingdom.

Director of Renal Unit and Laboratory of Experimental Nephrology; Department of Health Sciences, University of Milan; Milan, Italy.

Professor of Medicine; School of Medicine, University of California, Irvine; California, USA.